Recently, novel radiopharmaceuticals emerged as game changers in prostate cancer (PCa) with prostate-specific membrane antigen (PSMA) PET and in neuroendocrine tumor (NET) with somatostatin receptor (SSR) based PET. Here, FOLH1 is linked to neuroendocrine neoplasm.